Company: VRCA
Filing Date: 2025-12-23
Form Type: 424B3
Source: 0001193125-25-330986
Chunk: 0

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-23
Form: 424B3
Chunk 0
---
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-292140

PROSPECTUS

14,756,230 Shares

Common Stock

This prospectus relates to the offer and resale from time to time of up to an aggregate 14,756,230 shares of our common stock, par value
$0.0001 per share (the “Resale Shares”), consisting of (i) 6,499,826 shares of common stock (the “Shares”), (ii) up to an aggregate of 5,305,164 shares of common stock that are issuable upon the exercise of pre-funded warrants to purchase shares of our common stock (the “Pre-Funded Warrants,” and such shares of common stock issuable upon exercise of the Pre-Funded Warrants, the “Pre-Funded Warrant Shares”) and (iii) up to an aggregate of 2,951,240 shares of common stock that are issuable upon the exercise of
warrants to purchase shares of common stock (the “Common Warrants,” and such shares of common stock issuable upon exercise of the Common Warrants, the “Common Warrant Shares”) (the
Pre-Funded Warrants, together with the Common Warrants, are collectively referred to as the “Warrants”, and the Pre-Funded Warrant Shares, together with the
Common Warrant Shares, the “Warrant Shares”), by the selling stockholders named herein, together with any additional selling stockholders listed in a prospectus supplement (together with any of such stockholders’ transferees,
pledgees, donees or successors). The Shares and the Warrants were acquired by the selling stockholders named herein pursuant to securities purchase agreements, each dated November 23, 2025 (each a “Purchase Agreement,” and together,
the “Purchase Agreements”), in transactions more fully described in the section titled “Prospectus Summary.”

We
are registering the offer and sale of the Resale Shares from time to time by the selling stockholders to satisfy the registration rights granted in connection with the issuance of the Shares and the Warrants. We will not receive any proceeds from
the sale of the Resale Shares by the selling stockholders. However, we would receive proceeds from any cash exercise of the Pre-Funded Warrants or Common Warrants as follows: (i) if any Pre-Funded Warrants are exercised for cash, the exercise price of $0.0001 per share; and (ii)